^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Vyglxia (troriluzole)

i
Other names: BHV-4157, FC-4157
Associations
Company:
Biohaven
Drug class:
Glutamatergic modulator
Associations
1m
Troriluzole in Adult Participants With Spinocerebellar Ataxia (clinicaltrials.gov)
P3, N=299, Active, not recruiting, Biohaven Pharmaceuticals, Inc. | Trial completion date: Oct 2025 --> Jun 2026
Trial completion date
|
Vyglxia (troriluzole)
4ms
Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder (clinicaltrials.gov)
P3, N=589, Completed, Biohaven Pharmaceuticals, Inc. | Active, not recruiting --> Completed
Trial completion
|
Vyglxia (troriluzole)
4ms
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder (clinicaltrials.gov)
P3, N=700, Active, not recruiting, Biohaven Pharmaceuticals, Inc. | Trial completion date: Jun 2025 --> Nov 2025 | Trial primary completion date: Jun 2025 --> Nov 2025 | Recruiting --> Active, not recruiting
Enrollment closed • Trial completion date • Trial primary completion date
|
Vyglxia (troriluzole)
5ms
GBM AGILE: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (clinicaltrials.gov)
P2/3, N=1280, Recruiting, Global Coalition for Adaptive Research | Trial completion date: Jun 2028 --> Jun 2030 | Trial primary completion date: Jun 2026 --> Jun 2028
Trial completion date • Trial primary completion date
|
IDH wild-type
|
temozolomide • Stivarga (regorafenib) • lomustine • VT1021 • AZD1390 • Hepacid (pegargiminase) • paxalisib (GDC-0084) • dianhydrogalactitol (VAL-083) • Vyglxia (troriluzole)
5ms
BED IN 46: Methamphetamine and Troriluzole (clinicaltrials.gov)
P1, N=40, Recruiting, University of Kentucky | Not yet recruiting --> Recruiting
Enrollment open
|
Vyglxia (troriluzole)
7ms
BED IN 46: Methamphetamine and Troriluzole (clinicaltrials.gov)
P1, N=40, Not yet recruiting, University of Kentucky
New P1 trial
|
Vyglxia (troriluzole)
10ms
Troriluzole in Adult Participants With Spinocerebellar Ataxia (clinicaltrials.gov)
P3, N=299, Active, not recruiting, Biohaven Pharmaceuticals, Inc. | N=218 --> 299
Enrollment change
|
Vyglxia (troriluzole)
11ms
Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder (clinicaltrials.gov)
P3, N=1200, Enrolling by invitation, Biohaven Pharmaceuticals, Inc. | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
Trial completion date • Trial primary completion date
|
Vyglxia (troriluzole)
11ms
Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder (clinicaltrials.gov)
P3, N=700, Active, not recruiting, Biohaven Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
Vyglxia (troriluzole)
11ms
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder (clinicaltrials.gov)
P3, N=700, Recruiting, Biohaven Pharmaceuticals, Inc. | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
Trial completion date • Trial primary completion date
|
Vyglxia (troriluzole)
1year
Trial in Adult Subjects With Spinocerebellar Ataxia (clinicaltrials.gov)
P2/3, N=141, Completed, Biohaven Pharmaceuticals, Inc. | Active, not recruiting --> Completed
Trial completion
|
Vyglxia (troriluzole)
1year
Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control (clinicaltrials.gov)
P=N/A, N=909, Active, not recruiting, Biohaven Therapeutics Ltd. | Enrolling by invitation --> Active, not recruiting
Enrollment closed
|
Vyglxia (troriluzole)